NewCelX

Company Overview

Snapshot

Founded in October 2008 by Michel Revel, NewCelX operates with 11–50 employees and has raised a total of $45.35M across 9 funding rounds from 11 investors. The company completed a reverse merger with NLS Pharmaceutics in October 2025, leading to its public listing on NASDAQ.

Business overview

NewCelX is a biotechnology company focused on developing innovative cell-based and small-molecule therapies for neurodegenerative and metabolic diseases. The company leverages an integrated platform that combines advanced stem-cell technologies with neuroscience expertise to create scalable, regenerative treatments. Its core products, IsletRx and AstroRx, target conditions such as Amyotrophic Lateral Sclerosis (ALS) and Type 1 Diabetes, serving the pharmaceutical and life sciences markets within the Health Tech & Life Sciences sector.

Strategic signal

In October 2025, NewCelX completed a reverse merger with NLS Pharmaceutics, resulting in its listing on NASDAQ. This strategic move provides NewCelX with enhanced access to public capital markets and increased visibility, signaling a significant step towards accelerating the development and commercialization of its cell-based and small-molecule therapies for neurodegenerative and metabolic diseases.

Company Intelligence Q&A

What was a significant recent corporate development for NewCelX?

In October 2025, NewCelX completed a reverse merger with NLS Pharmaceutics Ltd., leading to its public listing on NASDAQ. This transaction was a pivotal step for the company's market presence and access to capital.

What was the outcome of the shareholder vote regarding the merger?

In September 2025, NLS Pharmaceutics shareholders approved the merger with Kadimastem (now NewCelX) and related proposals at an Extraordinary General Meeting, paving the way for the combined entity.

Did NewCelX receive any recent grants?

In July 2025, the BIRD Foundation approved an additional milestone payment to Kadimastem (now NewCelX) and iTolerance for the continued co-development of their Type 1 Diabetes cell therapy, highlighting ongoing support for the ITOL-102 program.

What recent patent approval did NewCelX receive?

In September 2025, NewCelX (formerly Kadimastem) and NLS Pharmaceutics announced a Hong Kong patent covering cell-selection and enrichment technology for IsletRx, their diabetes treatment.

What is the company's current strategic focus following the merger?

In November 2025, NewCelX provided a business and strategic roadmap update following the closing of the merger with NLS Pharmaceutics Ltd., outlining its plans for advancing its cell-based and small-molecule therapies.